The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Fioricet with Codeine
Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate · BUTALBITAL 50 mg/1; ACETAMINOPHEN 300 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE 30 mg/1 · Capsule · Oral · Actavis Pharma, Inc.
NDC 52544-0082-01 · 100 CAPSULE in 1 BOTTLE, PLASTIC · ANDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$15.60per dosage unitgross, before rebates — matched by drug name · 2024
- Medicaid generic ceiling (FUL)$6.72per CAPweighted avg manufacturer price $3.8398 · Oct 1, 2025
- List price (WAC, as filed)$1,928.39per packageTeva Pharmaceuticals USA · Jan 1, 2026
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00591-2641-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$7.24per unit
middle half $5.39–$7.76 · 133 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $7.24
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
2%of plans cover it
tier 3 · prior auth 21% · step therapy 0% · qty limit 95%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$1,762.70
Reported to Texas DSHS · 2026 annual filing · Actavis Pharma, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for butalbital, acetaminophen, caffeine and codeine phosphate (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,140.15 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Opioid Analgesic REMS Shared System REMS
Regulatory
- Application
- ANDA076560
- TE code
- AB
- Approval date
- Jun 10, 2004
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate (Capsule)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Actavis Pharma, Inc. | BUTALBITAL 50 mg/1; ACETAMINOPHEN 300 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE 30 mg/1 | Aug 26, 2026 | Sep 3, 2026 |
| Actavis Pharma, Inc. | CODEINE PHOSPHATE 30 mg/1; BUTALBITAL 50 mg/1; CAFFEINE 40 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Lgm Pharma Solutions, Llc | BUTALBITAL 50 mg/1; ACETAMINOPHEN 325 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE 30 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | BUTALBITAL 300 mg/1; ACETAMINOPHEN 50 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE 30 mg/1 | Jul 22, 2026 | Aug 22, 2026 |
| Actavis Pharma, Inc. | CODEINE PHOSPHATE 325 mg/1; BUTALBITAL 50 mg/1; CAFFEINE 40 mg/1; ACETAMINOPHEN 30 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Lgm Pharma Solutions, Llc | BUTALBITAL 325 mg/1; ACETAMINOPHEN 50 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE 30 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Actavis Pharma, Inc. | ACETAMINOPHEN 300 mg/1; BUTALBITAL 50 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE 30 mg/1 | Jul 15, 2026 | Jul 16, 2026 |
| Actavis Pharma, Inc. | ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE 30 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Lgm Pharma Solutions, Llc | ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1; CAFFEINE 40 mg/1; CODEINE PHOSPHATE 30 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Fioricet with Codeine — NDC 52544-0082-01," retrieved September 3, 2026, https://drugdashboards.com/drug/52544008201.
Free to cite with attribution — see how the data is put together.